- Deucrictibant data shows single-dose durability without symptom reoccurrence in the majority of HAE attacks treated
- First-ever bradykinin B2 receptor mechanism-on-mechanism prophylactic/on-demand data supports potential for deucrictibant portfolio
- Clinically validated biomarker assay has potential to eventually expand treatment opportunities of deucrictibant into additional forms of bradykinin-mediated angioedema
- Epidemiologic data and cognitive interviews further elucidate the unmet needs in bradykinin-mediated angioedema
ZUG, Switzerland, June 02, 2025 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the 14th C1-Inhibitor Deficiency and Angioedema Workshop.
“Additional analyses of deucrictibant data demonstrate consistency in the clinical profile shown in both the prophylactic and on-demand treatment settings,” said Berndt Modig, Chief Executive Officer of Pharvaris. “Deucrictibant’s early-onset and durable treatment response in the on-demand setting, the maintenance of attack reduction for over a year and a half in the prophylactic setting, and the potential for deucrictibant to be used together in both the prophylactic and on-demand settings, if needed, provide additional evidence of deucrictibant’s potential in the treatment of bradykinin-mediated angioedema. Pharvaris continues to diligently execute on the deucrictibant clinical program and is planning for two pivotal data readouts in the next 18 months.”
Details of the presentations are outlined below:
Prophylaxis
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study, an oral presentation by Emel Aygören-Pürsün, M.D. The ongoing Phase 2 CHAPTER-1 open-label extension (OLE) study provides further evidence on the long-term safety and efficacy of oral deucrictibant for prevention of HAE attacks. The attack rate has remained low, irrespective of baseline attack rate, for over a year and a half in OLE participants. When evaluating mechanism-on-mechanism responses, the response to icatibant for on-demand treatment of breakthrough attacks appeared to be maintained when used for breakthrough attacks during prophylactic treatment with deucrictibant.
Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris, stated, “Deucrictibant remains the only drug in development for bradykinin-mediated angioedema that has the potential to both prevent attacks and treat them when they occur. The data from the ongoing study further bolsters the potential value proposition of deucrictibant as it provides initial evidence that a bradykinin B2 receptor antagonist can effectively manage a breakthrough attack during treatment with a B2 receptor antagonist, if it were to occur. We believe further confirming these post-hoc open-label findings in our ongoing CHAPTER-3 study would provide additional evidence on the potential of deucrictibant to help address unmet needs of people living with bradykinin-mediated angioedema.”
